Semaglutide is another GLP‐1 analogue in ongoing phase‐II studies to explore the safety, tolerability and efficacy of semaglutide as a single‐use drug in NASH.87 A potential combined therapy with firscocostat and cilofexor (discussed below) is also in the pipeline. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.